With the primary focus in Parkinson’s disease, Solvemed Group leverages its proprietary machine learning technology to develop novel diagnostic-predictive digital biomarkers to enable first-in-class, accurate, early and cost-effective diagnostic and monitoring tools.
Focus: Diagnostics and drug discovery platform
Team: Hugo Chrost and Michal Wlodarski
Spaces are limited to a maximum of 10 companies per cohort. Contact Marco to know more or to apply.Contact Marco
Copyright © 2023 Stevenage Bioscience Catalyst